The company is completing a strategically compelling combination with MTL Cannabis to create Canada's leading medical cannabis company. Canopy has established a comprehensive ecosystem for the U.S. THC market through a non-controlling interest in Canopy USA, which includes ownership of Acreage Holdings, Wana Wellness, and other cannabis-related entities. Storz & Bickel devices benefited from strong seasonal demand with VEAZY becoming the company's best-selling device with the fastest ramp to 20,000 units sold.
Cyborg Score Rationale
The company improved earnings per share loss and demonstrates encouraging operational cash flow showing strong financial health. However, analysts have lowered price targets citing uncertainties about gross margins and regulatory impacts.
Top Insights
MTL Cannabis acquisition expected to close before end of March 2026 after receiving 99.97% shareholder approval
Trump's anticipated reclassification of marijuana could loosen federal constraints and open opportunities for research and cannabidiol products
Enterprise value approximately $960.68M with price-to-sales ratio around 1.85
Canada medical cannabis segment delivering strong performance with focus on high quality and insured patient segment
Named Competitors
Premium Cannabis Brands — Competing licensed cannabis producers in North America
Vaporization Devices — Premium vaporization technology and devices
Multi-State Operators — Vertically integrated U.S. cannabis operations
Recent Developments
(February 2026) MTL Cannabis shareholders approved acquisition with 99.97% support; closing expected by end of March 2026
(February 2026) Q3 FY2026 results showed double-digit revenue growth to C$90.39M and improved EPS loss to C$0.18
(January 2026) Strategic recapitalization completed extending all debt maturity dates to 2031